Universal Beteiligungs und Servicegesellschaft mbH Has $24.01 Million Stock Position in Labcorp Holdings Inc. $LH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH trimmed its Labcorp stake by 17.5%, selling 20,190 shares and retaining 95,349 shares worth $24.01 million (about 0.12% of the company).
• Insiders have been net sellers recently: CEO Adam H. Schechter sold 8,705 shares (~$2.44M) and EVP Brian J. Caveney sold 1,500 shares, with insiders offloading 16,113 shares (~$4.55M) over the past three months and now owning 0.84%.
• Labcorp beat EPS estimates for the quarter ($4.07 vs. $3.95) while revenue of $3.52B slightly missed consensus, issued FY2026 EPS guidance of 17.55–18.25, and declared a $0.72 quarterly dividend (1.1% yield).

Universal Beteiligungs und Servicegesellschaft mbH decreased its position in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) by 17.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 95,349 shares of the medical research company's stock after selling 20,190 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.12% of Labcorp worth $24,010,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of LH. JPL Wealth Management LLC acquired a new stake in shares of Labcorp in the third quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Labcorp in the fourth quarter worth about $26,000. Motco acquired a new stake in shares of Labcorp in the third quarter worth about $32,000. Eagle Bay Advisors LLC acquired a new stake in shares of Labcorp in the fourth quarter worth about $29,000. Finally, Hantz Financial Services Inc. lifted its position in shares of Labcorp by 48.8% in the third quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company's stock worth $35,000 after buying an additional 40 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company's stock.

Insider Transactions at Labcorp

In related news, CEO Adam H. Schechter sold 8,705 shares of the business's stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the transaction, the chief executive officer directly owned 80,773 shares in the company, valued at $22,613,209.08. The trade was a 9.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Brian J. Caveney sold 1,500 shares of the business's stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total value of $429,465.00. Following the transaction, the executive vice president owned 30,107 shares in the company, valued at $8,619,935.17. This represents a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 16,113 shares of company stock valued at $4,547,450. 0.84% of the stock is currently owned by insiders.

Labcorp Trading Down 0.4%

Labcorp stock opened at $263.84 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The business's 50-day simple moving average is $272.36 and its 200-day simple moving average is $268.00. The firm has a market capitalization of $21.68 billion, a PE ratio of 25.22, a PEG ratio of 1.81 and a beta of 1.02. Labcorp Holdings Inc. has a 52 week low of $218.76 and a 52 week high of $293.72.

Labcorp (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The firm had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. During the same period in the previous year, the company posted $3.45 earnings per share. The company's quarterly revenue was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Equities research analysts forecast that Labcorp Holdings Inc. will post 17.67 earnings per share for the current year.

Labcorp Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp's payout ratio is currently 27.53%.

Analyst Ratings Changes

A number of brokerages have weighed in on LH. Evercore reaffirmed an "outperform" rating and issued a $300.00 price target on shares of Labcorp in a research report on Wednesday, April 8th. Wall Street Zen cut Labcorp from a "buy" rating to a "hold" rating in a research report on Saturday, April 4th. Robert W. Baird boosted their price target on Labcorp from $313.00 to $326.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 18th. Piper Sandler boosted their price target on Labcorp from $270.00 to $300.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 24th. Finally, JPMorgan Chase & Co. boosted their price target on Labcorp from $319.00 to $330.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $307.20.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.